EGRX Stifel webcast: Ready-to-use Angiomax mentioned more prominently than on prior EGRX webcasts; no doubt, this is due to the CAFC’s en banc rehearing of the Angiomax patent case (#msg-118484166).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”